Melanoma News and Research

Latest Melanoma News and Research

Schizophrenia linked to lack of Vitamin D: study

Researchers at Queensland Brain Institute have found that babies born with low vitamin D levels are twice as likely to develop schizophrenia later in life. This could mean that it may be possible to prevent schizophrenia, which affects almost 200,000 Australians.

7 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

University of Maryland School of Medicine orders AVANCE III 950 US2 NMR spectrometer from Bruker

Bruker Corporation announces a major order from the University of Maryland School of Medicine for its ultra-high field AVANCE III 950 US2 NMR spectrometer. The 950 MHz Nuclear Magnetic Resonance magnet and spectrometer will help University of Maryland researchers to unravel the mysteries of molecules and develop new agents to treat cancer, AIDS and other diseases.

7 Sep 2010

Unpleasant short term side-effects of sunburn dont put off sun-seeking Brits

The research - commissioned by Superdrug and Cancer Research UK as part of their joint campaign to encourage people to enjoy the sun safely this summer - highlights the worrying lengths sun-seeking Brits are prepared to go to in search of a tan.

31 Aug 2010

RXR-alpha protein helps to protect pigment cells from invasive melanoma: Research

New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling "co-conspirators" in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads.

31 Aug 2010

Researcher develops new plaque brachytherapy technique to treat eye cancer

Rare but devastating, eye cancer can strike anyone at any time and treating it often requires radiation that leaves half of all patients partially blind.But a new technique developed by Scott Oliver, MD, assistant professor at the University of Colorado School of Medicine, may change all that.

30 Aug 2010

Promising skin cancer drug in the near horizon

A new drug has been developed to combat a deadly form of skin cancer – melanoma. The drug, PLX4032, was tested on 32 melanoma patients who had a key mutation in their tumors. 26 of these patients responded favorably says the study published in the New England Journal of Medicine.

30 Aug 2010

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Cascade Technologies, Inc. announced today that its wholly owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule.

27 Aug 2010

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

An experimental drug designed to treat cancers with a particular genetic fault has shown promising results in a small clinical trial.

27 Aug 2010

V Foundation Wine Celebration raises fund for cancer research

The 12th Annual Wine Celebration benefitting The V Foundation took place August 6&7 in Napa Valley, raising $2.2 million for cancer research. The event, a signature fundraiser for sportscaster/coach Jim Valvano's eponymous foundation, has raised more than $35 million since 1998.

27 Aug 2010

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

CreAgri, Inc. announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.

26 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.

25 Aug 2010

BioAlliance Pharma launches Oravig drug in the U.S. market

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc..

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

mBeach Software issues stockholder update for skin cancer diagnostic solutions

mBeach Software Inc. today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

21 Aug 2010

Melanoma News and Research

Latest Melanoma News and Research

Schizophrenia linked to lack of Vitamin D: study

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

University of Maryland School of Medicine orders AVANCE III 950 US2 NMR spectrometer from Bruker

Unpleasant short term side-effects of sunburn dont put off sun-seeking Brits

RXR-alpha protein helps to protect pigment cells from invasive melanoma: Research

Researcher develops new plaque brachytherapy technique to treat eye cancer

Promising skin cancer drug in the near horizon

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

V Foundation Wine Celebration raises fund for cancer research

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Treating metastatic melanoma tumors with specific genetic signature shows promising results

PLX4032 therapy results in tumor shrinkage in metastatic melanoma patients

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

BioAlliance Pharma launches Oravig drug in the U.S. market

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

mBeach Software issues stockholder update for skin cancer diagnostic solutions

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in